HC Wainwright Reaffirms Buy Rating for Dyne Therapeutics (NASDAQ:DYN)

Dyne Therapeutics (NASDAQ:DYN – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They currently have a $36.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 38.04% from the company’s […]

Related Keywords

China ,United States ,Piper Sandler ,Stifel Nicolaus ,Jasonp Rhodes ,Wildon Farwell ,Zurcher Kantonalbank Zurich Cantonalbank ,Allspring Global Investments Holdings ,Wetzel Investment Advisors Inc ,Sg Americas Securities ,China Universal Asset Management Co ,Dyne Therapeutics Inc ,Securities Exchange Commission ,Morgan Stanley ,Dyne Therapeutics ,Get Free Report ,Chardan Capital ,Exchange Commission ,Director Jason ,Investment Advisors ,Universal Asset Management ,Kantonalbank Zurich Cantonalbank ,Global Investments Holdings ,Dyne Therapeutics Daily ,Nasdaq Dyn ,Ladyn ,Medical ,Reiterated Rating ,Hc Wainwright ,